Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects

May 17, 2018, American Society of Clinical Oncology

A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free survival rate at four years was 89.4% with 6 months of therapy and 89.8% with 12 months of therapy. In addition, only 4% of women in the 6-month arm stopped trastuzumab early because of cardiac problems, compared with 8% in the 12-month arm.

"The Persephone trial's researchers worked closely with patient advocates. Everyone involved in this study is very excited by these results," said lead study author Helena Earl, MD, Professor of Clinical Cancer Medicine at the University of Cambridge in the United Kingdom. "We are confident that this will mark the first steps towards a reduction of the duration of trastuzumab to 6 months in many with HER2-positive breast cancer."

This is the largest trial to date examining the impact of shortening the duration of trastuzumab treatment, according to the authors. The results of the trial, Persephone, will be presented at the upcoming 2018 ASCO Annual Meeting in Chicago.

About the Study

Trastuzumab was granted FDA approval based on the results of three major trials reported in 2005. In these , the length of trastuzumab treatment was 12 months, and this treatment length quickly became the standard of care. Shortly thereafter, a small trial in Finland (FinHer) reported similar benefit from as little as 9 weeks of trastuzumab, prompting research interest in shortening treatment length to reduce side effects and costs.

In Persephone, half of the women took trastuzumab for 6 months and the other half for 12 months. Women also received chemotherapy (anthracycline-based, taxane-based, or a combination of both) while enrolled in the trial. The non-inferiority design allowed the trial to help determine whether reduced duration of treatment can be as good as the standard treatment within pre-specified limits, which are set before the trial starts.

Key Findings

The women in the trial were followed for a median of over five years. Researchers found that 89.4% of women in the 6-month arm and 89.8% in the12-month arm were alive and free of at four years. The trial demonstrated that 6 months of trastuzumab treatment was non-inferior to 12 months.

Only 4% of women who received trastuzumab for 6 months stopped treatment early due to heart problems, compared to 8% of those who took for 12 months.

Next Steps

The researchers are currently analyzing their results to determine the impact of treatment length on quality of life, with qualitative feedback from trial participants. A detailed cost-effectiveness analysis is also underway.

Professor Earl stated that more research needs to be done to define the particular patients for whom treatment duration can be safely reduced. The researchers plan to analyze blood and tissue samples collected within the trial to look for biomarkers to identify different risk groups.

Explore further: Six months of Herceptin could be as effective as 12 months for some women with HER2 positive breast cancer

More information: abstracts.asco.org/214/AbstView_214_217191.html

Related Stories

Six months of Herceptin could be as effective as 12 months for some women with HER2 positive breast cancer

May 17, 2018
For women with HER2 positive early-stage breast cancer taking Herceptin for six months could be as effective as 12 months in preventing relapse and death, and can reduce side effects, finds new research.

Adjuvant Trastuzumab did not improve outcomes for patients with HER2-low breast cancer

December 6, 2017
Adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, as defined as immunohistochemistry ...

New drug combo improves survival of women with rare uterine cancer

April 10, 2018
Adding the monoclonal antibody drug trastuzumab—already used to treat certain breast cancers—to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from ...

Trastuzumab: No negative impact on cardiac function

January 3, 2018
Long-term follow-up results of the NRG Oncology trial NSABP B-31 have shown that the addition of trastuzumab to adjuvant chemotherapy does not negatively affect cardiac function in women with node-positive, human epidermal ...

Adding a second HER2 blocker may lower chance of invasive breast cancer for some women

June 5, 2017
A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although ...

New antibody-drug conjugate shows early promise for patients with metastatic HER2-positive breast cancer

April 21, 2015
An investigational antibody-drug conjugate called MM-302 was safe, tolerable, and showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer, according to data from a phase ...

Recommended for you

'Liquid biopsy' predicts lymphoma therapy success within days, study finds

August 20, 2018
A blood test can predict which patients with a type of cancer called diffuse large B cell lymphoma are likely to respond positively to initial therapy and which are likely to need more aggressive treatment, according to a ...

Study shows how to make (and destroy) a metastatic cancer cell

August 20, 2018
Many cancers become especially dangerous only when they metastasize from their site of origin to faraway tissues such as lung, brain or bone. Now, a University of Colorado Cancer Center study published today in the Proceedings ...

Research team develops predictor for immunotherapy response in melanoma

August 20, 2018
In a new study, researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a novel type of immunotherapy. ...

Study details effect of radiation exposure on hormone deficiencies

August 20, 2018
In a new study, University of Cincinnati (UC) researchers, in collaboration with Massachusetts General Hospital, have detailed the effect of radiation exposure on the development of hormone deficiency in pediatric and young ...

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.